17752 Effects of ruxolitinib cream on affected body areas in patients with vitiligo: Subgroup analysis from a 52-week, randomized, double-blind trial

Abstract

Ruxolitinib cream is a Janus kinase inhibitor under investigation for vitiligo treatment. Vitiligo lesion location affects repigmentation likelihood. Meta-analyses of phototherapy and topical calcineurin inhibitors for vitiligo demonstrated no evidence of marked (≥75%) repigmentation of hands/feet. This 52-week, randomized, double-blind, phase 2 study (NCT03099304) enrolled adult patients with vitiligo that included depigmentation ≥0.5% of body surface area (BSA) on the face and ≥3% of, BSA on nonfacial areas.